Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00383474
First received: September 29, 2006
Last updated: April 14, 2015
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2012
  Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)